Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Radius Health has completed the third and final equity tranche of its $91m financing round, the proceeds of which will be used in the development of BA058 Injection.
Subscribe to our email newsletter
The third tranche included $21.4m in equity financing from Radius’ current investors, bringing gross proceeds received to date from the $91m financing to $78.7m.
The company intends to use the finances primarily to advance the ongoing Phase 3 clinical study of BA058 Injection, the company’s novel anabolic (bone-building) drug for the treatment of osteoporosis.
Data from the Phase 3 study is likely to form the primary basis for an efficacy claim to support applications for marketing authorization of BA058 Injection in the US and Europe.